Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Albireo Pharma Inc. (ALBO)

33.37   0.73 (2.24%) 10-01 08:23
Open: 32.64 Pre. Close: 32.64
High: 34.54 Low: 32.64
Volume: 214,518 Market Cap: 634M
Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. The company is headquartered in Boston, Massachusetts and currently employs 39 full-time employees. The company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. The company has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 34.589 - 34.783 34.783 - 34.96
Low: 32.143 - 32.389 32.389 - 32.615
Close: 33.011 - 33.37 33.37 - 33.699

Technical analysis

as of: 2020-09-30 4:38:29 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 46.85     One year: 57.23
Support: Support1: 25.73    Support2: 21.41
Resistance: Resistance1: 40.11    Resistance2: 49.00
Pivot: 36.63
Moving Average: MA(5): 32.92     MA(20): 35.65
MA(100): 28.25     MA(250): 23.75
MACD: MACD(12,26): 0.90     Signal(9): 1.84
Stochastic oscillator: %K(14,3): 7.49     %D(3): 14.03
RSI: RSI(14): 49.52
52-week: High: 49.00  Low: 11.26  Change(%): 73.4
Average Vol(K): 3-Month: 41380  10-Days: 33852

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
ALBO has closed above bottom band by 22.3%. Bollinger Bands are 62% wider than normal. The large width of the bands suggest high volatility as compared to ALBO's normal range. The bands have been in this wide range for 16 bars. This is a sign that the current trend might continue.

Headline News

Tue, 29 Sep 2020
Short Interest On Albireo Pharma, Inc. (ALBO) Might Be Rising - Invest Million

Fri, 25 Sep 2020
Albireo Pharma Inc (ALBO) Stock Decreases -12.93% This Week; Should You Buy? - InvestorsObserver

Sun, 20 Sep 2020
Analysts Anticipate Albireo Pharma Inc (NASDAQ:ALBO) Will Post Quarterly Sales of $1.87 Million - MarketBeat

Fri, 11 Sep 2020
Q3 2021 EPS Estimates for Albireo Pharma Inc (NASDAQ:ALBO) Decreased by Analyst - MarketBeat

Fri, 11 Sep 2020
Is Albireo Pharma Inc (ALBO) a Stock to Watch This Week? - InvestorsObserver

Tue, 08 Sep 2020
Is Albireo Pharma Inc (ALBO) a Winner in the Biotechnology Industry? - InvestorsObserver

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 19
Shares Float (M) 12
% Held by Insiders 6.46
% Held by Institutions 71.35
Shares Short (K) 1,440
Shares Short P. Month (K) 582

Stock Financials

EPS -5.980
EPS Est This Year -3.640
EPS Est Next Year -3.440
Book Value (p.s.) 5.950
Profit Margin
Operating Margin -693.91
Return on Assets (ttm) -26.7
Return on Equity (ttm) -78.8
Qtrly Rev. Growth 53.0
Gross Profit (p.s.) 0.508
Sales Per Share 0.594
EBITDA (p.s.) -4.113
Qtrly Earnings Growth
Operating Cash Flow (M) -73
Levered Free Cash Flow (M) -42

Stock Valuations

PE Ratio -5.58
PEG Ratio
Price to Book value 5.61
Price to Sales 56.18
Price to Cash Flow -8.65

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.